Table of Contents

company-logo

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Molecular Partners Dividend Announcement

• Molecular Partners does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Molecular Partners dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Molecular Partners Dividend History

Molecular Partners Dividend Yield

Molecular Partners current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Molecular Partners stock? Use our calculator to estimate your expected dividend yield:

Molecular Partners Financial Ratios

P/E ratio-2.65
PEG ratio0.02
P/B ratio1.19
ROE-39.16%
Payout ratio0.00%
Current ratio14.33
Quick ratio14.33
Cash Ratio6.30

Molecular Partners Dividend FAQ

Does Molecular Partners stock pay dividends?
Molecular Partners does not currently pay dividends to its shareholders.
Has Molecular Partners ever paid a dividend?
No, Molecular Partners has no a history of paying dividends to its shareholders. Molecular Partners is not known for its dividend payments.
Why doesn't Molecular Partners pay dividends?
There are several potential reasons why Molecular Partners would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Molecular Partners ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Molecular Partners has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Molecular Partners a dividend aristocrat?
Molecular Partners is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Molecular Partners a dividend king?
Molecular Partners is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Molecular Partners a dividend stock?
No, Molecular Partners is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Molecular Partners stocks?
To buy Molecular Partners you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Molecular Partners stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.